SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors weigh its dominant position in the GLP-1 weight-loss market against intensifying competition and a recent high-profile clinical trial setback for its primary rival, Novo Nordisk. While the community is actively debating the timing of a potential oral drug launch, sentiment remains focused on the company's ability to maintain its market lead despite ongoing analyst downgrades and broader sector volatility.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is currently experiencing high volatility as investors weigh milestone euphoria against earnings anxiety, with market participants closely monitoring the company's progress on nuclear isotope licensing and Department of Energy approvals. Community discussions are centered on the upcoming business update, with traders debating whether these regulatory advancements will provide a significant catalyst or if the stock is being pumped ahead of potentially lackluster financial results.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is seeing intense volatility and active community debate as investors weigh strong earnings growth and AI infrastructure demand against market-wide profit-taking and valuation concerns. While many traders are buying the dip in anticipation of continued hyperscaler expansion, others remain cautious due to recent institutional selling and sector-wide sentiment shifts following major semiconductor conference announcements.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing extreme volatility during its Nasdaq debut, with investors debating the company's military-grade autonomous drone technology against concerns regarding its financial disclosures and typical IPO trading patterns. Market participants are actively tracking the stock's frequent trading halts while speculating on the long-term viability of its battlefield-tested software.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital is currently trending as investors speculate on a major tenant announcement following the strategic hiring of a CFO with extensive experience in data center financing. While community sentiment remains polarized between long-term holders eyeing a potential squeeze and skeptics demanding official PR to validate the company's behind-the-meter energy model, trading activity remains volatile as participants monitor volume for a sustained breakout.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is gaining attention as investors react to long-term clinical data published in JAMA Neurology, which reinforces the efficacy and durability of Briumvi in treating relapsing multiple sclerosis. The community remains focused on the company's revenue growth trajectory, potential for a buyout, and the strategic impact of its new national awareness campaign.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as investors digest a series of strategic pivots, including the acquisition of parking app SpotHero and the launch of 'Uber Autonomous Solutions' to court robotaxi developers. While some in the community express skepticism over heavy R&D spending and long-term viability, others view these movescoupled with significant insider buying by the CFOas a strong signal that the company is effectively positioning itself as the central, asset-light marketplace for future autonomous mobility.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Investors in Fannie Mae (FNMA) are bracing for volatility as they weigh the potential for federal release and privatization against uncertainty over the timing of legislative action and the impact of the administration's current mortgage bond purchasing mandates. The community remains deeply divided, with many long-term holders citing interest from high-profile investors like Michael Burry and Bill Ackman as a reason to maintain conviction, while others express frustration over the lack of concrete timelines and the stock's recent downward price pressure.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a massive surge in trading volume and social interest as investors anticipate major announcements regarding its photonic engines and external light source products at the upcoming OFC and Nvidia GTC conferences. While some community members remain focused on the need for verified purchase orders and revenue, others view current price action as institutional accumulation in anticipation of a structural shift toward optical interconnects in AI infrastructure.

Elbit Systems Ltd. engages in the defense and homeland security sector. It develops and supplies airborne, land and naval systems and products for defense, homeland security, and commercial applications. The firm also provides training and support services. The company was founded in 1996 and is headquartered in Haifa, Israel.

Elbit Systems Ltd.

Elbit Systems is trending as investors monitor ongoing contract wins in the global defense sector, while community discussions focus on its technical performance and valuation compared to industry peers. Market participants are also weighing the impact of its recent dividend increase and elevated demand for military technologies against a backdrop of regional geopolitical volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HeartBeam Reports Fourth Quarter and Full Year 2025 Results

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, has reported its financial and operational results for the...

<ul><li>HeartBeam’s technology uniquely capable of assessing possible heart attacks outside of traditional clinical settings</li><li>ALIGN-ACS study expected to complete patient enrollment quickly</li><li>Milestone signifies key step toward future FDA indication expansion for heart attack assessment</li><li>Future indication expansion would unlock large market with over 20 million patients at risk of a heart attack</li></ul>SANTA CLARA, Calif.--(BUSINESS WIRE)-- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam, Inc.</a> (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the first patients have been enrolled in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The first patients were enrolled by Prof. Dr. Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade, Serbia. The initiation of the ALIGN-ACS pilot study represents a significant step toward collecting the data needed to support expanding the indication of the HeartBeam System beyond arrhythmia assessment to include heart attack assessment.Heart attacks remain the leading cause of death, with more than 20 million patients in the U.S. who are at risk. Patients often delay seeking care by 3–4 hours because symptoms can be vague or subtle, driving up mortality, complications, and cost of care. While a 12-lead ECG remains the standard of care for diagnosing a heart attack, there is no reliable method for physicians to assess possible heart attacks outside of a clinical setting. HeartBeam aims to fill this gap and shorten <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://newsroom.heart.org/news/acting-quickly-after-heart-attack-symptoms-start-can-be-a-heart-saver">“symptom-to-door” times</a>by enabling patients to record a clinical-grade ECG the moment symptoms begin, wherever they are. By capturing the heart’s electrical signals in 3D, from 3 non-coplanar dimensions, HeartBeam’s 3D ECG technology provides physicians with a high-fidelity, reliable way to assess possible heart attacks outside of a clinical setting.“Every minute matters during a heart attack, and early, accurate identification of a heart attack is essential to ensuring patients receive the care they need in a timely manner and improving outcomes,” said HeartBeam Scientific Advisory Board Chair C. Michael Gibson, MD, FRCP, FAHA, FSCAI, FACC, Interventional Cardiologist at Beth Israel Lahey and Professor of Medicine at Harvard Medical School. “HeartBeam’s technology has the potential to meaningfully change how quickly we evaluate patients by providing timely access to clinical-grade ECG data outside the hospital, enabling clinicians to accelerate triage decisions and intervene sooner.”The ALIGN-ACS pilot study is designed to enroll 100 patients presenting with chest pain in the emergency room (ER). Patients will be evaluated with both a standard 12-lead ECG and the HeartBeam device and both results will be compared with each patient’s final diagnosis at discharge. As the study is designed to enroll chest pain patients in the ER, enrollment is expected to progress quickly.The pilot study builds on multiple earlier <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/evidence#:~:text=Heart%20Attack%20Detection">proof of concept studies</a> demonstrating that a 3D ECG configuration similar to the HeartBeam device’s ability to detect heart attacks was similar in accuracy to a standard 12-lead ECG, including a study presented at the 2025 American Heart Association Scientific Sessions on the 3D approach. Learnings from the ALIGN-ACS pilot study will inform the design of a multicenter pivotal study that would serve as the basis of a future FDA submission.“HeartBeam was founded on the premise that since most heart attacks happen outside of a hospital, there should be a fast and easy way for patients and physicians to assess both symptoms and ECG data at home or anywhere,” said Robert Eno, Chief Executive Officer for HeartBeam. “The initiation of our pilot study for heart attack detection is a defining moment for HeartBeam as this is one of the largest clinical opportunities in cardiology. Our platform is uniquely positioned to deliver clinical-grade ECG insights at the moment symptoms occur and facilitate more timely action to close the ‘symptom-to-door’ gap.”This milestone aligns directly with HeartBeam’s key long-term growth initiatives, which also include the limited launch of the FDA-cleared HeartBeam System for arrhythmia assessment, ongoing development of the Company’s working-prototype 12-lead ECG patch monitor and advancement of its AI program. These initiatives collectively position HeartBeam to advance its vision for more accessible and intelligent cardiac care.About HeartBeam, Inc.HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam received FDA clearance for arrhythmia assessment for its 3D ECG technology in December 2024 and for its 12-Lead ECG synthesis software in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam.com</a>.Forward-Looking StatementsAll statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.sec.gov/">www.sec.gov</a>. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.1Cleared Indications for UseThe HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/indications">https://www.heartbeam.com/indications</a> for details on the intended use of its technology.MKT-109 v1&nbsp;View source version on businesswire.com: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260305231175/en/">https://www.businesswire.com/news/home/20260305231175/en/</a>Media Contact: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:media@heartbeam.com">media@heartbeam.com</a> Investor Relations Contact: Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:BEAT@mzgroup.us">BEAT@mzgroup.us</a> <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.mzgroup.us/">www.mzgroup.us</a>Source: HeartBeam, Inc.Released March 5, 2026Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

HeartBeam Announces First Patient Enrollments in Heart Attack Detection Pilot Study

HeartBeam starts ALIGN-ACS study to validate 3D ECG for home-based heart attack detection.

Others

<ul><li>Accelerates development of personalized cardiac AI on the HeartBeam platform for wellness and clinical applications, including assessing heart attack risk</li><li>Combines Mount Sinai’s world-class AI and clinical expertise with HeartBeam’s groundbreaking 3D ECG signal collection technology</li><li>HeartBeam is the only platform capable of collecting 12-lead ECG data from patients anytime, anywhere, over time – extending access beyond traditional clinical settings</li><li>Positions HeartBeam to expand from symptom-based cardiac rhythm monitoring into AI-enabled disease assessment and management</li></ul>SANTA CLARA, Calif.--(BUSINESS WIRE)-- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam, Inc.</a> (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the joint development and validation of next-generation AI-ECG algorithms. The collaboration will leverage HeartBeam’s patented ECG platform, which captures the heart’s electrical activity from 3 non-coplanar dimensions. The partnership marks a significant milestone in the Company’s long-term strategy to build an ecosystem around its platform and strengthen its leadership in AI-enabled cardiac monitoring.A core value driver of the collaboration is HeartBeam’s differentiated ability to generate longitudinal, high-fidelity synthesized 12-lead ECG datasets from patients in the home setting—data that has historically been inaccessible to AI development. This creates a foundation for developing increasingly personalized algorithms earlier in the care journey and enabling 12-lead ECG assessments in real-world settings, supporting both wellness use cases and clinically relevant assessments, such as heart attack risk.The combination of HeartBeam’s continuously expanding dataset and Mount Sinai’s clinically annotated 12-lead ECG data can accelerate the training and validation of various AI models. Over time, this collaboration will result in a data engine that is expected to support the development of increasingly personalized algorithms—positioning HeartBeam to expand into new clinical indications and reimbursement pathways.“We believe expanding access to 12-lead ECG data assessment beyond the clinic is one of the biggest opportunities,” said Robert Eno, Chief Executive Officer of HeartBeam. “By pairing our ability to gather high-fidelity real-world ECG data with Mount Sinai’s extensive clinical data resources and AI expertise, we are creating a differentiated cardiac intelligence engine that can scale beyond traditional care settings and broaden the reach of predictive cardiology, ultimately expanding our clinical and commercial opportunity.”Under the collaboration, HeartBeam’s in-house AI team led by Lance Myers, PhD, a leading authority on AI applications in biosensor technologies, will work closely with Mount Sinai researchers to develop, train and validate a suite of advanced AI-ECG algorithms intended for deployment onto the HeartBeam platform. Joshua Lampert, MD, FACC, a pioneer in AI-ECG and cardiovascular deep learning research and clinician recognized for his excellence in patient care, Vivek Reddy, MD, an internationally renowned electrophysiologist and innovator, and Girish N. Nadkarni, MD, MPH, the Chief AI Officer of the Mount Sinai Health System and Chair of the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai, will help guide the scientific and clinical development of the partnership.“While AI-ECG has rapidly progressed as a field over recent years, there is room for improvement in the portability and scalability of such algorithms beyond acquisition devices that require complex multi-electrode systems. Additionally, current approaches struggle to leverage deep learning inference opportunities outside of traditional health care settings, which is where dynamic changes to cardiovascular health first start before patients present for care. The collaboration addresses these vital needs. By combining deep learning tools with the ability to record full 3-dimensional cardiac electrical activity without cables, we can provide clinically meaningful and operationally pragmatic models at scale regardless of environment,” said Dr. Lampert, Cardiac Electrophysiologist, Medical Director of Machine Learning for Mount Sinai Fuster Heart Hospital and Director of Cardiovascular Artificial Intelligence for the Windreich Department of Artificial Intelligence and Human Health at Mount Sinai.Pairing HeartBeam’s innovative hardware and approach to cardiac waveform engineering with Mount Sinai’s advanced AI and clinical expertise creates a powerful foundation for developing tools that dynamically meet modern patient and clinician needs wherever they are.“Heart disease doesn’t only show up during a brief visit to the clinic. This collaboration gives us an opportunity to bring powerful clinical-grade heart monitoring into patients’ daily lives,” said Dr. Nadkarni. “By combining advanced AI with HeartBeam’s ability to capture full 12-lead ECG signals from home over time, we can study the heart in ways that simply haven’t been possible before—helping clinicians detect risk earlier and guide care more precisely.”“This collaboration addresses an important need by leveraging deep learning and 3-dimensional waveform data for scalable diagnostic and predictive purposes, allowing insights beyond even expert human ability,” added Dr. Reddy, who serves as the Director of Cardiac Arrhythmia Services for Mount Sinai Health System.Together, the two organizations aim to accelerate the development of high-value algorithms that can be deployed broadly across HeartBeam’s platform. These AI models may include patient-relevant wellness insights, condition-focused assessments, and applications for chronic condition management. By enabling AI models to operate on longitudinal, real-world synthesized 12-lead ECG data rather than isolated clinical snapshots, the collaboration has the potential to significantly expand the addressable market for AI-driven cardiac monitoring. The collaboration could unlock new opportunities in preventive cardiology, chronic disease management, and remote patient monitoring—further reinforcing HeartBeam’s position as a leader in cardiac intelligence platforms.About the Mount Sinai Health SystemMount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 10 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News &amp; World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News &amp; World Report® “Best Hospitals” Honor Roll for 2025-2026.For more information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.mountsinai.org/">https://www.mountsinai.org/</a> or find Mount Sinai on <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/mountsinainyc?utm_medium=cpc&amp;utm_source=google&amp;utm_content=googlesem&amp;utm_campaign=mshs-respiratoryinstitute">Facebook</a>, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.instagram.com/mountsinainyc/?hl=en">Instagram</a>, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/mountsinainyc/">LinkedIn</a>, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://twitter.com/mountsinainyc?utm_medium=cpc&amp;utm_source=google&amp;utm_content=googlesem&amp;utm_campaign=mshs-respiratoryinstitute">X</a>, and <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/mountsinainy">YouTube</a>.About HeartBeam, Inc.HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam.com</a>.Forward-Looking StatementsAll statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.sec.gov/">www.sec.gov</a>. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.1Cleared Indications for UseThe HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/indications">https://www.heartbeam.com/indications</a> for details on the intended use of its technology.&nbsp;View source version on businesswire.com: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260310761343/en/">https://www.businesswire.com/news/home/20260310761343/en/</a>Media Contact: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:media@heartbeam.com">media@heartbeam.com</a>Investor Relations Contact: Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:BEAT@mzgroup.us">BEAT@mzgroup.us</a> <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.mzgroup.us/">www.mzgroup.us</a>Source: HeartBeam, Inc.Released March 10, 2026Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

HeartBeam and Mount Sinai Announce Strategic AI Collaboration to Bring Clinical-Grade Heart Monitoring into the Home

HeartBeam and Mount Sinai partner to develop AI-ECG algorithms for remote heart attack assessment.

<ul><li>Marks HeartBeam’s transition to commercial company</li><li>Rapidly growing practice and highly engaged member population to enable broad adoption</li><li>Enables efficient scaling of additional preventive cardiology and executive health programs</li><li>Establishes initial foothold in structured direct pay healthcare segment representing 5 million patients</li></ul>SANTA CLARA, Calif.--(BUSINESS WIRE)-- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam, Inc.</a> (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced a commercial partnership with <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://clearcardio.com/">ClearCardio™</a>, a leading preventive cardiology practice that has served thousands of patients through advanced heart health screening and personalized prevention programs. In addition to serving as HeartBeam’s first commercial customer, ClearCardio also plans to make an investment in HeartBeam, reflecting strong strategic alignment.The partnership includes an initial staged rollout to ensure a seamless patient and physician experience, and plans for broader expansion to thousands of highly engaged members across multiple U.S. geographies. ClearCardio offers its members a cardiac prevention program to monitor cardiac risk factors and will incorporate HeartBeam’s synthesized 12-lead ECG technology into the program for arrhythmia assessment.HeartBeam’s patented cable-free 3D ECG technology captures the heart’s electrical signals in three non-coplanar dimensions and synthesizes them into a 12-lead ECG. This allows patients to obtain a high-fidelity, clinical-grade ECG reading for their arrhythmia from the comfort of home, or wherever they happen to be, representing a new level of convenience and peace of mind.“ClearCardio was founded on the belief that proactive care, including earlier detection and continuous vigilance, can meaningfully change patient outcomes,” said John Osborne, MD, PhD, Chief Medical Officer of ClearCardio, “HeartBeam’s synthesized 12-lead ECG technology for arrhythmia assessments fits directly into that mission by giving our patients an unprecedented ability to capture meaningful cardiac data whenever symptoms occur while being connected directly to our physicians. This is a major step forward in preventive cardiology.”This collaboration highlights HeartBeam’s fit within a premium, innovation-first segment where patient engagement is high, new product adoption moves quickly, and physicians seek differentiated solutions for patients who are willing to pay for proactive peace of mind. The agreement positions HeartBeam to replicate this model across additional concierge care networks, preventive cardiology groups, and executive health programs nationwide. Additionally, this collaboration supports the validation of HeartBeam’s pricing and subscription-based business model.“ClearCardio becoming our first commercial customer sends a clear message to the market. We believe HeartBeam’s technology is ready, the need is real, and the demand is building,” stated Robert Eno, Chief Executive Officer at HeartBeam. “We believe this is the beginning of a new growth phase for HeartBeam and the first of many milestones to come across our key growth initiatives.”The initial agreement with ClearCardio is structured as a Letter of Intent (LOI), outlining the commercial terms and a collaborative rollout plan, including a subscription fee per patient. During the initial deployment phase, HeartBeam and ClearCardio intend to negotiate and execute a definitive agreement.This commercial milestone aligns directly with HeartBeam’s long-term growth strategy, which includes the limited launch of the FDA-cleared HeartBeam System for arrhythmia assessment, future indication for heart attack assessment, ongoing development of the Company’s working-prototype 12-lead ECG patch monitor and advancement of its AI program. These initiatives collectively position HeartBeam to advance its vision for more accessible and intelligent cardiac care.About ClearCardioClearCardio, LLC is a leading preventive cardiology practice that has served thousands of patients through advanced heart health screening and personalized prevention programs. At the forefront of cardiovascular innovation, ClearCardio specializes in early detection and precision treatment of arterial plaque—the root cause of heart attacks—using cutting-edge AI-powered imaging and non-invasive diagnostics. Working with high-performing professionals, executives, and public safety leaders who know their health impacts more than just themselves, ClearCardio physicians help members detect cardiac disease early, quantify personal risk with clarity and treat the root cause, not just the symptoms. Visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.clearcardio.com/">www.clearcardio.com</a> for more information.About HeartBeam, Inc.HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam.com</a>.Forward-Looking StatementsAll statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.sec.gov/">www.sec.gov</a>. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.1Cleared Indications for UseThe HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/indications">https://www.heartbeam.com/indications</a> for details on the intended use of its technology.&nbsp;View source version on businesswire.com: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260304586980/en/">https://www.businesswire.com/news/home/20260304586980/en/</a>Media Contact: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:media@heartbeam.com">media@heartbeam.com</a>Investor Relations Contact: Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:BEAT@mzgroup.us">BEAT@mzgroup.us</a> <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.mzgroup.us/">www.mzgroup.us</a>Source: HeartBeam, Inc.Released March 4, 2026Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

HeartBeam Announces First Commercial Customer as ClearCardio Brings Groundbreaking 12-Lead ECG Technology to High-Growth Preventive Cardiology Market

HeartBeam partners with ClearCardio to commercialize its 3D ECG tech for preventive cardiac care.

Strategic Partnerships and Platform Plays Power New Momentum Across Tech and Healthcare

Markets open the session with strategic partnerships, infrastructure consolidation, and breakthrough technologies dominating the corporate news cycle; several companies are positioning themselves at the intersection of innovation and scalable commercialization. $INKT, $VTAK, $KBLB, $APP, $BEAT, $SGN, $STGW

Heartbeam Stock Jumps After AI Collaboration With Mount Sinai

HeartBeam shares are trading higher Tuesday following a partnership with Mount Sinai to accelerate next-gen AI-ECG algorithms.read more...

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a strategic collaboration with the Icahn...

HeartBeam to Attend Investor and Industry Conferences in March, Focused on Providing Updates on Commercial Launch and Unveiling 12-Lead ECG Extended Wear Patch

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that management will attend key investor and...

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the first patients have been enrolled in...

HeartBeam to Host Fourth Quarter Full Year 2025 Results Conference Call on Thursday, March 12, 2026 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, March 12, 2026 at...

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

BEAT
HeartBeam Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest BEAT News

BEATHeartBeam Inc